These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

273 related items for PubMed ID: 25012839

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A choice of radionuclide: Comparative outcomes and toxicity of ruthenium-106 and iodine-125 in the definitive treatment of uveal melanoma.
    Takiar V, Voong KR, Gombos DS, Mourtada F, Rechner LA, Lawyer AA, Morrison WH, Garden AS, Beadle BM.
    Pract Radiat Oncol; 2015; 5(3):e169-e176. PubMed ID: 25423888
    [Abstract] [Full Text] [Related]

  • 3. Ruthenium-106 eye plaque brachytherapy in the conservative treatment of uveal melanoma: a mono-institutional experience.
    Perri P, Fiorica F, D'Angelo S, Lamberti G, Parmeggiani F, Martini A, Carpenteri F, Colosimo C, Micucci M, Perazzini L, De Gugliemo E, Berretta M, Sebastiani A, Cartei F.
    Eur Rev Med Pharmacol Sci; 2012 Dec; 16(14):1919-24. PubMed ID: 23242717
    [Abstract] [Full Text] [Related]

  • 4. (106)Ru plaque brachytherapy for uveal melanoma: factors associated with local tumor recurrence.
    Barker CA, Francis JH, Cohen GN, Marr BP, Wolden SL, McCormick B, Abramson DH.
    Brachytherapy; 2014 Dec; 13(6):584-90. PubMed ID: 24880583
    [Abstract] [Full Text] [Related]

  • 5. Ruthenium brachytherapy for uveal melanoma, 1979-2003: survival and functional outcomes in the Swedish population.
    Bergman L, Nilsson B, Lundell G, Lundell M, Seregard S.
    Ophthalmology; 2005 May; 112(5):834-40. PubMed ID: 15878063
    [Abstract] [Full Text] [Related]

  • 6. Tumor control, eye preservation, and visual outcomes of ruthenium plaque brachytherapy for choroidal melanoma.
    Marconi DG, de Castro DG, Rebouças LM, Bernardes Gil GO, Fogaroli RC, Conte Maia MA, Gobo Silva ML, Assis Pellizzon AC, Motono Chojniak MM.
    Brachytherapy; 2013 May; 12(3):235-9. PubMed ID: 22436517
    [Abstract] [Full Text] [Related]

  • 7. Neoadjuvant proton beam irradiation vs. adjuvant ruthenium brachytherapy in transscleral resection of uveal melanoma.
    Böker A, Pilger D, Cordini D, Seibel I, Riechardt AI, Joussen AM, Bechrakis NE.
    Graefes Arch Clin Exp Ophthalmol; 2018 Sep; 256(9):1767-1775. PubMed ID: 29907945
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Ruthenium plaque radiation therapy for iris and iridociliary melanomas.
    Razzaq L, Keunen JE, Schalij-Delfos NE, Creutzberg CL, Ketelaars M, de Keizer RJ.
    Acta Ophthalmol; 2012 May; 90(3):291-6. PubMed ID: 20670343
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pigmented episcleral deposits after brachytherapy of uveal melanoma.
    Toivonen P, Kivelä T.
    Ophthalmology; 2006 May; 113(5):865-73. PubMed ID: 16530837
    [Abstract] [Full Text] [Related]

  • 13. Radiation related complications after ruthenium plaque radiotherapy of uveal melanoma.
    Summanen P, Immonen I, Kivelä T, Tommila P, Heikkonen J, Tarkkanen A.
    Br J Ophthalmol; 1996 Aug; 80(8):732-9. PubMed ID: 8949719
    [Abstract] [Full Text] [Related]

  • 14. Predicting local control of choroidal melanomas following ¹⁰⁶Ru plaque brachytherapy.
    Papageorgiou KI, Cohen VM, Bunce C, Kinsella M, Hungerford JL.
    Br J Ophthalmol; 2011 Feb; 95(2):166-70. PubMed ID: 20889528
    [Abstract] [Full Text] [Related]

  • 15. Retina dose as a predictor for visual acuity loss in 106Ru eye plaque brachytherapy of uveal melanomas.
    Heilemann G, Fetty L, Blaickner M, Nesvacil N, Zehetmayer M, Georg D, Dunavoelgyi R.
    Radiother Oncol; 2018 Jun; 127(3):379-384. PubMed ID: 29452902
    [Abstract] [Full Text] [Related]

  • 16. Long-term follow-up of Ru-106/Rh-106 brachytherapy for posterior uveal melanoma.
    Lommatzsch PK, Werschnik C, Schuster E.
    Graefes Arch Clin Exp Ophthalmol; 2000 Feb; 238(2):129-37. PubMed ID: 10766281
    [Abstract] [Full Text] [Related]

  • 17. Ruthenium-106 brachytherapy.
    Pe'er J.
    Dev Ophthalmol; 2012 Feb; 49():27-40. PubMed ID: 22042011
    [Abstract] [Full Text] [Related]

  • 18. Ruthenium plaque radiation for iris and iridociliary melanomas: development of dry eyes?
    Razzaq L, de Keizer RJ.
    Br J Ophthalmol; 2010 Nov; 94(11):1549-50. PubMed ID: 20516146
    [No Abstract] [Full Text] [Related]

  • 19. Ruthenium brachytherapy for uveal melanomas: Factors affecting the development of radiation complications.
    Pagliara MM, Tagliaferri L, Azario L, Lenkowicz J, Lanza A, Autorino R, Caputo CG, Gambacorta MA, Valentini V, Blasi MA.
    Brachytherapy; 2018 Nov; 17(2):432-438. PubMed ID: 29275868
    [Abstract] [Full Text] [Related]

  • 20. Use of Ruthenium-106 Brachytherapy for Iris Melanoma: The Scottish Experience.
    Agraval U, Sobti M, Russell HC, Lockington D, Ritchie D, Cauchi P, Kemp EG, Chadha V.
    Br J Ophthalmol; 2018 Jan; 102(1):74-78. PubMed ID: 28600302
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.